Exciting change is on the way! Please join us at nsf.gov for the latest news on NSF-funded research. While the NSF Science360 page and daily newsletter have now been retired, there’s much happening at nsf.gov. You’ll find current research news on the homepage and much more to explore throughout the site. Best of all, we’ve begun to build a brand-new website that will bring together news, social media, multimedia and more in a way that offers visitors a rich, rewarding, user-friendly experience.

Want to continue to receive email updates on the latest NSF research news and multimedia content? On September 23rd we’ll begin sending those updates via GovDelivery. If you’d prefer not to receive them, please unsubscribe now from Science360 News and your email address will not be moved into the new system.

Thanks so much for being part of the NSF Science360 News Service community. We hope you’ll stay with us during this transition so that we can continue to share the many ways NSF-funded research is advancing knowledge that transforms our future.

For additional information, please contact us at NewsTravels@nsf.gov

Today's Video

A link between Celebrex and heart valve calcification

A Big-Data analysis of patient records at Vanderbilt University has found a link specifically between Celebrex and heart valve calcification. A team of researchers started out by testing celecoxib, the active compound in Celebrex, on valve cells in an effort to see if it could double as an aortic stenosis therapy. It made the problem worse. To confirm their theory about a link between celecoxib and valve calcification, the researchers analyzed more than 8,600 relevant, anonymous patient records from Vanderbilt University Medical Center. They checked whether there was a link between Celebrex use and aortic valve disease, and, after correcting for other risk factors, discovered that patients who had taken Celebrex had a 35 percent increased prevalence of valve disease.

Provided by Vanderbilt University
Runtime: 0:30